Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | GFRA2 | O00451 | 1/20 | 0.36 |
| ▸ | GFRA3 | O60609 | 1/20 | 0.36 |
| ▸ | PPIB | P23284 | 1/20 | 0.35 |
| ▸ | PPIA | P62937 | 1/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.33 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31360588 | 0.75 | IDO1 (0.50) | IDO1FFAR1SLC6A4GFRA2GFRA3 | |
| SCHEMBL12320928 | 0.73 | IDO1 (0.54) | IDO1FFAR1SLC6A4 | |
| SCHEMBL12017975 | 0.72 | IDO1 (0.61) | IDO1FFAR1SLC6A4GFRA2GFRA3 | |
| SCHEMBL21142124 | 0.70 | IDO1 (0.54) | IDO1FFAR1SLC6A4GFRA2GFRA3 | |
| SCHEMBL17090854 | 0.70 | IDO1 (0.54) | IDO1FFAR1SLC6A4 | |
| SCHEMBL8529487 | 0.70 | IDO1 (0.54) | IDO1FFAR1GFRA2GFRA3 | |
| SCHEMBL21810402 | 0.70 | SUCNR1 (0.54) | FFAR1GFRA2GFRA3 | |
| SCHEMBL8530467 | 0.70 | IDO1 (0.50) | IDO1FFAR1GFRA2GFRA3 | |
| SCHEMBL1746643 | 0.70 | IDO1 (0.50) | IDO1FFAR1SLC6A4GFRA2GFRA3 | |
| SCHEMBL12320173 | 0.69 | SLC6A4 (0.51) | IDO1SLC6A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596051-B1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2022-04-27 | — | — | EP | disclosed |
| US-20200087281-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LIMITED (IN) | 2020-03-19 | — | — | US | disclosed |
| EP-3596051-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | Impetis Biosciences Ltd. (IN) | 2020-01-22 | — | — | EP | disclosed |
| WO-2018167800-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LIMITED (IN) | 2018-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087281-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | GPR119, GPR65, GPR88 | IDO1 1968/4885FFAR1 25/4885SLC6A4 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.